Calamos Advisors
EBAC

Calamos Advisors’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Calamos Advisors’s Portfolio EBAC Stock Details EBAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-100,000
Closed -$992K – 1459
2022
Q3 		$992K Buy
+100,000
New +$987K ﹤0.01% 949

Other funds holding EBAC

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Calamos Advisors's EBAC Position: Q4 2022 in Review

Calamos Advisors sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q4 2022, closing a stake of 100,000 shares — an estimated $992K sold.

Calamos Advisors first reported a position in EBAC in Q3 2022 and held it in 1 quarter. The position peaked at $992K in Q3 2022. 50 funds tracked by Wall St. Rank hold EBAC as of Q4 2022.

  • Calamos Advisors reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q4 2022 after selling out during the quarter.
  • Calamos Advisors sold 100,000 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q4 2022, an estimated $992K.
  • Calamos Advisors first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q3 2022 and held it in 1 quarter.
  • Calamos Advisors's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $992K in Q3 2022.
  • 50 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q4 2022.

Based on Calamos Advisors's 13F filing for Q4 2022, filed 26 Jan 2023.